Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 1
2014 1
2015 1
2016 1
2017 3
2018 1
2019 2
2020 2
2021 3
2022 2
2023 3
2024 1
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
Bustos Fernández LM, Man F, Lasa JS. Bustos Fernández LM, et al. Dig Dis. 2023;41(5):798-809. doi: 10.1159/000528954. Epub 2023 Jan 11. Dig Dis. 2023. PMID: 36630947 Clinical Trial.
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is associated with diarrhea-predominant irritable bowel syndrome (IBS-D). Probiotics like Saccharomyces boulardii CNCM I-745 (Sb) may be efficacious in balancing the microbiota. ...SIBO was assessed by …
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is associated with diarrhea-predominant irritable bowel syndrome (IBS-D). Pr …
Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
Brun P, Scarpa M, Marchiori C, Sarasin G, Caputi V, Porzionato A, Giron MC, Palù G, Castagliuolo I. Brun P, et al. PLoS One. 2017 Jul 21;12(7):e0181863. doi: 10.1371/journal.pone.0181863. eCollection 2017. PLoS One. 2017. PMID: 28732069 Free PMC article.
BACKGROUND: We evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscular anomalies in an IBS-type mouse model of gastrointestinal motor dysfunctions elicited by Herpes Simplex Virus type 1 (HSV-1) exposure. ...RESULTS: S. boula …
BACKGROUND: We evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscular anomalies in an IBS …
Saccharomyces boulardii's impact on pediatric diarrhea-predominant irritable bowel syndrome: animal model findings.
Jin X, Guo P, Jin X, Xia W, Liu X, Sheng W, Zhu D. Jin X, et al. Pediatr Res. 2025 Nov 10. doi: 10.1038/s41390-025-04482-3. Online ahead of print. Pediatr Res. 2025. PMID: 41214290
RESULTS: Clinical data have shown that Saccharomyces boulardii treatment significantly improves IBS-D symptoms in children, as evidenced by the reduction in IBS symptom severity scale score and normalization of stool morphology. ...The specific role of …
RESULTS: Clinical data have shown that Saccharomyces boulardii treatment significantly improves IBS-D symptoms in child …
Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.
Gu Y, Wang C, Qin X, Zhou B, Liu X, Liu T, Xie R, Liu J, Wang B, Cao H. Gu Y, et al. Pharmacol Res. 2022 Jul;181:106291. doi: 10.1016/j.phrs.2022.106291. Epub 2022 Jun 8. Pharmacol Res. 2022. PMID: 35690329
Saccharomyces boulardii (Sb) is a widely used fungal probiotic in treating various digestive diseases, including irritable bowel syndrome (IBS). However, the specific mechanisms of Sb relieving IBS remain unclear. The abnormal serotonin transporter (SE …
Saccharomyces boulardii (Sb) is a widely used fungal probiotic in treating various digestive diseases, including irritable bow …
Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome.
Constante M, De Palma G, Lu J, Jury J, Rondeau L, Caminero A, Collins SM, Verdu EF, Bercik P. Constante M, et al. Neurogastroenterol Motil. 2021 Mar;33(3):e13985. doi: 10.1111/nmo.13985. Epub 2020 Sep 21. Neurogastroenterol Motil. 2021. PMID: 32955166
Using this model, we tested the therapeutic potential of the probiotic yeast Saccharomyces boulardii strain CNCM I-745 (S. bou) and investigated underlying mechanisms. METHODS: Germ-free Swiss Webster mice were colonized with fecal microbiota from an IBS+A pa …
Using this model, we tested the therapeutic potential of the probiotic yeast Saccharomyces boulardii strain CNCM I-745 (S. bou …
The effects of Saccharomyces boulardii on rat colonic hypermotility induced by repeated water avoidance stress and the potential mechanism.
Liu J, Ren H, Yuan F, Shao M, Luo H. Liu J, et al. PeerJ. 2022 Nov 22;10:e14390. doi: 10.7717/peerj.14390. eCollection 2022. PeerJ. 2022. PMID: 36438584 Free PMC article.
BACKGROUND: Saccharomyces boulardii (Sb) has been reported to have the potential to regulate gut motility. ...A diarrhea-predominant irritable bowel syndrome (IBS-D) model in rats was induced using the WAS method. Gut motility was evaluated by stool pellet ex …
BACKGROUND: Saccharomyces boulardii (Sb) has been reported to have the potential to regulate gut motility. ...A diarrhea-predo …
Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review.
Ahlawat GM, Singh PK. Ahlawat GM, et al. Curr Ther Res Clin Exp. 2023 Oct 18;99:100721. doi: 10.1016/j.curtheres.2023.100721. eCollection 2023. Curr Ther Res Clin Exp. 2023. PMID: 38021264 Free PMC article. Review.
Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential risks remain unclear. OBJECTIVE: This review aims to explore the therapeutic potential of probiotics, particularly Saccharomyces bo …
Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential r …
Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J. Bafutto M, et al. Arq Gastroenterol. 2013 Oct-Dec;50(4):304-9. doi: 10.1590/S0004-28032013000400012. Arq Gastroenterol. 2013. PMID: 24474234 Free article.
OBJECTIVE: Evaluate the effects of mesalazine alone, combined therapy of mesalazine with liophylised Saccharomyces boulardii or alone on symptoms of IBS-D patients. METHODS: Based on Rome III criteria, 53 IBS-D patients (18 year or more) were included. …
OBJECTIVE: Evaluate the effects of mesalazine alone, combined therapy of mesalazine with liophylised Saccharomyces boulardii o …
Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Kabir MA, et al. Mymensingh Med J. 2011 Jul;20(3):397-401. Mymensingh Med J. 2011. PMID: 21804501 Clinical Trial.
Several studies with probiotics have shown promising results in the treatment of IBS. One of the probiotics used was saccharomyces boulardii. This is a randomized double blind placebo controlled clinical trial of S. boulardii in diarrhoea predominant …
Several studies with probiotics have shown promising results in the treatment of IBS. One of the probiotics used was saccharomyces …
23 results